Sodium thiosulfate

Generic Medicine Info
Indications and Dosage
Cyanide poisoning
Adult: To be given after 300 mg of sodium nitrite has been administered over 5-20 minutes: 12.5 g of sodium thiosulfate (50 ml of a 25% solution or 25 ml of a 50% solution) given over 10 minutes. If symptoms of cyanide toxicity recur, the dose may be repeated after 30 minutes at half the initial doses.
Child: To be given after 4-10 mg/kg of sodium nitrite (max: 300 mg) has been administered over 5-20 minutes: 400 mg/kg of sodium thiosulfate, as a 25 or 50% solution (max: 12.5 g). If symptoms of cyanide toxicity recur, the dose of nitrite and thiosulfate may be repeated after 30 minutes at half the initial doses.
Oedematous sodium-retaining conditions.
Special Precautions
May irritate eyes, skin and respiratory tract.
Adverse Reactions
Osmotic disturbances. Oral: catharsis (at high doses).
Drug Interactions
Decreases toxicity of cisplatin through rapid chemical inactivation of its platinum component.
Description: Sodium thiosulfate acts as an antidote in the treatment of cyanide poisoning. It acts as a sulphur-donating substrate for the enzyme rhodanese, thus speeding up the conversion of cyanide to thiocyanide, which is relatively non toxic. It is often used in combination with sodium nitrite but may be used alone in less severe poisoning.
Absorption: Poorly absorbed from the GI tract.
Distribution: Distributed throughout the extracellular fluid.
Excretion: Rapidly excreted in the urine.
MIMS Class
Antidotes & Detoxifying Agents
Disclaimer: This information is independently developed by MIMS based on Sodium thiosulfate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in